Good news - as expected. We already knew that all initial...

Good news - as expected.  We already knew that all initial patients developed an immune response.  Good to hear that all patients at all dosing levels did likewise.  The top line results announcement in December will of course be of huge interest, with the hope that there will be initial indications of clinical effectiveness.   There would be little point proceeding with Phase 2 if the IMU team had no indications of clinical effectiveness, but the Phase 1b was a dose escalation study of relatively short duration in a relatively small sample, so don't expect anything miraculous.  

Nice photo of the dinner.  "Guests from GSK and Merck" - very interesting.  Assuming here that Axel doesn't count as a "guest" - so he must have brought someone else along.

Merck and GSK are doing a joint study of Merck's Keytruda in combo with a GSK drug, announced just under 3 years ago: https://www.gsk.com/en-gb/media/pre...py-combination-as-potential-cancer-treatment/

And of course Merck did the big deal with Hopper's Viralytics....

So - plenty here to keep my interest in Imugene simmering away.

Cheers

Dave